type 2 diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group will receive daily 150 mg CoQ10 as three divided doses for 12 weeks. Each capsule consists of 50 mg CoQ10. Intervention 2: Placebo group will receive daily three cap
Treatment - Other
Placebo
Intervention group will receive daily 150 mg CoQ10 as three divided doses for 12 weeks. Each capsule consists of 50 mg CoQ10.
Placebo group will receive daily three capsules containing corn flour for12 weeks.
Sponsors
Vice-chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Patients with type 2 diabetes 2- Willing to participate 3- Duration of type 2 diabetes > 1 year 4- HbA1c40 2- Past history of MI or stroke 3-Patients with any of the following conditions: liver disease, kidney disease, or thyroid disease 4-Supplement use for at least 8 weeks before intervention till the end of study 5- Treatment with warfarin 6-BP>160/90 7-Pregnancy and lactation 8-Compliance<70% 9-Change in type or dose of medication for at least 8 weeks before intervention till the end of study 10-Treatment with insulin
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Paraxonase. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: spectrophotometry.;Total antioxidant capacity. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: FRAP.;MDA. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: spectrophotometry.;Hs-CRP. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: turbidometry.;Triglyceride. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Gop-PAP.;TC. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: enzymatic.;LDL. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Friedewald formula.;HDL. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: precipitation.;HbA1c. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: chromatography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Insuline. Timepoint: before intervaention, 12 weeks after intervention. Method of measurement: RIA.;FBS. Timepoint: before intervaention, 12 weeks after intervention. Method of measurement: enzymatic. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed